Mauna Kea Technologies reported its monthly share capital data for July 2026, disclosing 195,296,487 shares comprising the capital in circulation as of July 31, 2026. The medical device company, listed on Euronext Growth Paris under ticker ALMKT (ISIN: FR0010609263), also confirmed that both its gross total voting rights and net total voting rights stand at 196,383,354. This disclosure ensures transparency regarding ownership structure and voting power distribution for investors monitoring the firm’s equity base.

The filing was made in accordance with Article L233-8-II of the Commercial Code and Article 223-16 of the General Regulations of the AMF. These regulatory requirements mandate regular updates on share capital composition to maintain market integrity and inform stakeholders of any changes in voting rights thresholds.

Share Capital Breakdown

The following table details the share capital and voting rights figures as reported by Mauna Kea Technologies:

The gross number of voting rights serves as the basis for calculating regulatory thresholds. In line with Article 223-11 of the General Regulations of the AMF, this figure includes all shares carrying voting rights, even those without active voting privileges. The net number of voting rights excludes shares with suspended voting rights and reflects the count exercisable in general meetings, published per the AMF recommendation of July 17, 2007.

What the Numbers Show

The alignment between gross and net voting rights at 196,383,354 indicates that no voting rights were suspended during the reporting period. This parity suggests a stable shareholder base without temporary restrictions on voting power, which can sometimes occur due to legal disputes or specific corporate governance actions. For investors tracking control dynamics, this consistency implies that all theoretical voting power is currently actionable in shareholder meetings.

Mauna Kea Technologies manufactures and sells Cellvizio®, a real-time in vivo cellular imaging platform used globally across various medical specialties. The technology enables physicians to monitor disease progression, assess reactions in real time, and guide surgical interventions. For further details, investors may visit www.maunakeatech.com or contact investor relations at investors@maunakeatech.com .

Mauna Kea Technologies (Euronext Growth: ALMKT) has announced two new peer-reviewed clinical studies that reinforce the diagnostic value of its Cellvizio® probe and needle-based confocal laser endomicroscopy (p/nCLE) platform for pancreatic cystic lesions (PCLs). The findings demonstrate significant improvements in diagnostic accuracy and physician agreement, addressing critical challenges in distinguishing mucinous from non-mucinous cysts and detecting high-grade dysplasia. These results support the company’s strategy to scale adoption across U.S. centers and integrate artificial intelligence into its diagnostic workflow.

The first study, published in Gastrointestinal Endoscopy, was an international interobserver assessment involving 15 independent physicians of varying experience levels. The research evaluated the reproducibility of pancreatic cyst diagnostics when Cellvizio imaging was added to standard evaluation protocols. The addition of real-time cellular imaging increased the accuracy for distinguishing mucinous versus non-mucinous cysts to 96%. Furthermore, subtype-specific accuracy rose to approximately 85%, and agreement among the independent observers improved significantly. This reproducibility across clinicians is cited as a key factor for broad clinical adoption.

The second study, published in Techniques and Innovations in Gastrointestinal Endoscopy, focused on an nCLE-guided artificial intelligence algorithm designed to detect high-grade dysplasia or early cancer within intraductal papillary mucinous neoplasms (IPMNs). In higher-risk, non-gastric IPMN subtypes, the AI algorithm achieved 87% accuracy, a substantial increase from the 53% accuracy rate of conventional methods. The study noted comparable sensitivity across subtypes, providing early evidence supporting the company’s roadmap to deploy AI-assisted decision support tools on the Cellvizio platform.

Clinical Impact and Expert Commentary

Dr. Somashekar (Som) Krishna, Professor of Medicine and Director of Advanced Endoscopy at The Ohio State University Wexner Medical Center, highlighted the clinical stakes of accurate diagnosis. He noted that in pancreatic cyst diagnosis, errors can lead to either unnecessary surgery for benign cysts or missed cancers. In the ongoing multicenter CLIMB study evaluating EUS-nCLE, adding real-time EUS-nCLE to standard evaluation raised diagnostic accuracy from 73% to 85%. This improvement reduced unnecessary surgery for benign cysts by more than 40% and cut missed cancers roughly six-fold. Dr. Krishna emphasized that these gains were produced by 15 international endosonographers new to the technique, demonstrating consistent performance across users.

Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, stated that the growing body of independent, peer-reviewed evidence confirms the unique value of Cellvizio in providing a window into pancreatic cysts that no other technology offers. He added that avoiding unnecessary surgeries and detecting cancers earlier strengthens the company’s conviction as it scales adoption and brings AI-assisted diagnosis to the platform.

What the Numbers Show

The data reveals a clear divergence between conventional diagnostic methods and those augmented by Cellvizio technology. While standard evaluations struggle with consistency, the integration of nCLE imaging raises overall accuracy to 96% for primary classification. More notably, the application of AI to this imaging data bridges a significant gap in detecting high-risk lesions, nearly doubling the accuracy rate from 53% to 87% in non-gastric IPMN subtypes. This suggests that the combination of hardware-based cellular imaging and software-driven analysis addresses both the reproducibility and sensitivity limitations inherent in traditional pancreatic cyst management.

Mauna Kea Technologies is listed on Euronext Growth under the ticker ALMKT. The company’s 2025 Annual Report was filed with the Autorité des marchés financiers (AMF) on April 30, 2026.